Skip to content

Arcutis Biotherapeutics, Inc. ARQT Other intangible assets—net

Other intangible assets—net at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$217.34M-15.9%
LQD
Liquidia CorporationLQDA
$2.89M-7.1%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s other intangible assets—net?
Arcutis Biotherapeutics, Inc. (ARQT) reported other intangible assets—net of $14.25M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s other intangible assets—net changed year-over-year?
Arcutis Biotherapeutics, Inc.'s other intangible assets—net decreased by 13.6% year-over-year, from $16.5M to $14.25M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.